Malaysia Pharma and Healthcare Sector Report 2024-2025

Malaysia has one of Southeast Asia's most advanced pharmaceutical and healthcare sectors. Malaysia's healthcare system is divided into two segments: a taxpayer-funded and government-run system and a private sector. The public system, managed by the Ministry of Health (MoH), is the backbone of Malaysian healthcare, providing heavily subsidised healthcare to most of the population. The public healthcare system is based on a referral model, in which patients gain access to higher-tier services only after consultation with general practitioners or outpatient departments reveals that their treatment requires more specialised skills or advanced equipment. Meanwhile, private healthcare providers allow fee-paying patients to see specialists directly, which speeds up treatment but contributes to instances of excessive testing and treatment.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Malaysia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Malaysia
• Crystallise the forces both driving and restraining this sector in Malaysia
• Ascertain Malaysia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Malaysia.
• Build a clear picture of trends, output and consumption for specific sub-sectors